Pfizer Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everybody. Thank you for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs.
I'm very pleased to welcome Pfizer for this session. Joining us from the company is Chairman and CEO, Albert Bourla. Albert, thank you very much for joining us today, really appreciate your time. And thank you for everything that the company is doing with respect to COVID-19 on both the vaccine and treatment front. I know it's a tremendous effort, and we appreciate everything you're doing.
Thank you very much, Terence, and it's a great privilege and a great responsibility these days to work on a solution.
Questions & Answers
Great. Maybe to get started, COVID-19 is obviously going to have near and long-ranging impacts on the system, companies' business models, from delivery of care, clinical trial
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |